Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 0.90 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.90 |
| ▸ | MAPT | P10636 | 3/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.90 |
| ▸ | TP53 | P04637 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | PGR | P06401 | 2/20 | 0.90 |
| ▸ | ESRRG | P62508 | 2/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.90 |
| ▸ | HTR6 | P50406 | 2/20 | 0.90 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.90 |
| ▸ | EGFR | P00533 | 1/20 | 0.90 |
| ▸ | GBA1 | P04062 | 1/20 | 0.90 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.90 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL2412102 | 1.00 | ESR1 (0.90) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL28507550 | 0.96 | ESR1 (0.92) | ESR1ESR2MAPTMEN1TP53 | |
| Afimoxifene SCHEMBL7649806 | 0.95 | ESR1 (0.91) | ESR1ESR2MAPTMEN1TP53 | |
| Afimoxifene SCHEMBL7649812 | 0.95 | ESR1 (0.91) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 0.95 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073454-A4 | METHODS FOR TREATING HOT FLASHES AND GYNAECOMASTIA | PRAECIS PHARM INC (US) | 2005-03-09 | — | — | EP | claimed |
| EP-1073454-A1 | METHODS FOR TREATING HOT FLASHES AND GYNAECOMASTIA | Praecis Pharmaceuticals Incorporated (US) | 2001-02-07 | — | — | EP | claimed |
| WO-2000007599-A1 | PREVENTION OF ENDOMETRIOSIS SIGNS OR SYMPTOMS | HEINRICHS WILLIAM LEROY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999055358-A1 | METHODS FOR TREATING HOT FLASHES AND GYNAECOMASTIA | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1999-11-04 | — | — | WO | claimed |
| US-12208227-B2 | Precision bio-chemotronic system | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-01-28 | — | — | US | disclosed |
| CN-111787945-B | Engineered nanovesicles as checkpoint blockers for cancer immunotherapy | 北卡罗莱纳州立大学 | 2024-11-29 | — | — | CN | disclosed |
| US-20210145335-A1 | PRECISION BIO-CHEMOTRONIC SYSTEM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-05-20 | — | — | US | disclosed |
| CN-111787945-A | Engineered nanovesicles as checkpoint blockers for cancer immunotherapy | 北卡罗莱纳州立大学 | 2020-10-16 | — | — | CN | disclosed |
| CN-111629755-A | Particles for combined radiation therapy treatment of cancer | 施里昂医疗有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3672487-A1 | PRECISION BIO-CHEMOTRONIC SYSTEM | The Regents of The University of Michigan (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040898-A1 | PRECISION BIO-CHEMOTRONIC SYSTEM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-28 | — | — | WO | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2006033979-A1 | TREATMENT OF ANDROGEN - DEPRIVATION INDUCED OSTEOPOROSIS | GTX, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20050080143-A1 | Treatment of androgen-deprivation induced osteoporosis | GTX, INC. | 2005-04-14 | — | — | US | disclosed |
| EP-1073454-A4 | METHODS FOR TREATING HOT FLASHES AND GYNAECOMASTIA | PRAECIS PHARM INC (US) | 2005-03-09 | — | — | EP | disclosed |
| US-6703367-B1 | LUTEINIZING HORMONE RELEASING HORMONE (LHRH) ANTAGONIST IS ADMINISTERED TO PATIENT IN MENOPAUSE | PRAECIS PHARMACEUTICALS INC. | 2004-03-09 | — | — | US | disclosed |
| US-6265393-B1 | CONTINUOUS COADMINISTRATION OF LOW DOSES OF AN ESTROGEN AGENT AND A PROGESTIN AGENT TO MAINTAIN AN INDUCED STATE OF OLIGOMENORRHEA OR AMENORRHEA IN AN AFFLICTED WOMAN. | HEINRICHS WILLIAM LEROY (US) | 2001-07-24 | — | — | US | disclosed |
| EP-1073454-A1 | METHODS FOR TREATING HOT FLASHES AND GYNAECOMASTIA | Praecis Pharmaceuticals Incorporated (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000007599-A1 | PREVENTION OF ENDOMETRIOSIS SIGNS OR SYMPTOMS | HEINRICHS WILLIAM LEROY (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999055358-A1 | METHODS FOR TREATING HOT FLASHES AND GYNAECOMASTIA | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 1999-11-04 | — | — | WO | disclosed |